4542-72-7

Usage

Uses

Used in Pharmaceutical Industry:
1,4-Bis(2-bromoethyl)benzene is used as a key intermediate in the synthesis of various pharmaceuticals, contributing to the development of new drugs and improving the efficacy of existing medications.
Used in Specialty Chemicals Production:
1,4-Bis(2-broMoethyl)benzene serves as a vital component in the creation of specialty chemicals, which are utilized in a wide range of applications, from industrial processes to consumer products.
Used as a Crosslinking Agent in Polymer and Resin Manufacturing:
1,4-Bis(2-bromoethyl)benzene is employed as a crosslinking agent, enhancing the properties of polymers and resins by forming covalent bonds between polymer chains, thereby improving their stability, strength, and durability.
Safety Note:
It is important to acknowledge that 1,4-Bis(2-bromoethyl)benzene is considered to be moderately toxic and can cause skin and eye irritation upon contact. Therefore, it is crucial to handle this chemical with care and adhere to proper safety protocols when working with it.

Upstream product

• 36076-25-2 (4-methoxycarbonylmethylphenyl)acetic acid methyl ester 
• 36076-26-3 diethyl 2,2'-(1,4-phenylene)diacetate 
• 5140-03-4 2-[4-(2-hydroxyethyl)phenyl]ethan-1-ol 

Downstream Products

• 130800-03-2 2,2'-(1,4-phenylene)diethyl diiodide 
• 857579-88-5 2,5-bis-(2-bromo-ethyl)-1,3-dinitro-benzene 
• 157254-60-9 1,4-PBIT dihydrobromide 
• 1047626-87-8 1,4-bis(2-azidoethyl)benzene 
• 857543-12-5 (4-carboxy-2,6-dinitro-phenyl)-acetic acid 
• 1633-22-3 [2.2]Paracyclophan 
• 2913-24-8 [3.3]paracyclophane 
• 78965-35-2 2,5-dibromo-1,4-bis(2-bromoethyl)benzene 
• 3998-55-8 1,4-Bis(2-mercaptoethyl)benzene 

Relevant academic research and scientific papers

Synthesis and characterization of a novel iNOS/Akt inhibitor Se,Se′-1,4-phenylenebis(1,2-ethanediyl)bisisoselenourea (PBISe)-against colon cancer

Our studies demonstrate that substitution of sulfur with selenium in known iNOS inhibitor increases the compound's potency by several folds in variety of different cancers cell lines tested. Hence, this approach may be used as a strategy to increase the e

SULFONIMIDAMIDE COMPOUNDS AS NLRP3 MODULATORS

Described herein are compounds of Formula (I), Formula (I-A), and Formula (I-B), solvates thereof, tautomers thereof, and pharmaceutically acceptable salts of the foregoing, Further described herein are methods of inhibiting NLRP3 using said compounds, and methods of and compositions useful in treating NLRP3-dependent disorders.

FUNCTIONALIZED LONG-CHAIN HYDROCARBON MONO- AND DI-CARBOXYLIC ACIDS AND THEIR USE FOR THE PREVENTION OR TREATMENT OF DISEASE

This invention provides compounds of Formulae (IA), (IB), (IC), (ID), (IE), (IF), (IG), (IH), (IJ), (IK), (IL), (II), (III), (IIIA), and (IIIB); pharmaceutically acceptable salts and solvates thereof; and compositions thereof. This invention further provides methods for treating a disease, including but not limited to, liver disease or an abnormal liver condition; cancer (such as hepatocellular carcinoma or cholangiocarcinoma); a malignant or benign tumor of the lung, liver, gall bladder, bile duct or digestive tract; an intra- or extra-hepatic bile duct disease; a disorder of lipoprotein; a lipid-and-metabolic disorder; cirrhosis; fibrosis; a disorder of glucose metabolism; a cardiovascular or related vascular disorder; a disease resulting from steatosis, fibrosis, or cirrhosis; a disease associated with increased inflammation (such as hepatic inflammation or pulmonary inflammation); hepatocyte ballooning; a peroxisome proliferator activated receptor-associated disorder; an ATP citrate lyase disorder; an acetyl-coenzyme A carboxylase disorder; obesity; pancreatitis; or renal disease.

SULFONIMIDAMIDE COMPOUNDS AND COMPOSITIONS FOR TREATING CONDITIONS ASSOCIATED WITH NLRP ACTIVITY

In one aspect, compounds of Formula AA, or a pharmaceutically acceptable salt thereof, are featured: (Formula AA) or a pharmaceutically acceptable salt thereof, wherein the variables shown in Formula A can be as defined anywhere herein.

SULFONAMIDE DERIVATIVES AND USES THEREOF

The present disclosure relates to compounds of Formula (I) or (II): and to their prodrugs, pharmaceutically acceptable salts, pharmaceutical compositions, methods of use, and methods for their preparation. The compounds disclosed herein are useful for inhibiting the maturation of cytokines of the IL-1 family by inhibiting inflammasomes and may be used in the treatment of disorders in which inflammasome activity is implicated, such as inflammatory, autoinflammatory and autoimmune diseases and cancers.

COMPOUNDS AND COMPOSITIONS FOR TREATING CONDITIONS ASSOCIATED WITH NLRP ACTIVITY

In one aspect, compounds of Formula AA, or a pharmaceutically acceptable salt thereof, are featured.The variables shown in Formula AA are as defined in the claims. The compounds of formula AA are NLRP3 activity modulators and, as such, can be used in the treatment of metabolic disorders (e.g. Type 2 diabetes, atherosclerosis, obesity or gout), a disease of the central nervous system (e.g. Alzheimer's disease, multiple sclerosis, Amyotrophic Lateral Sclerosis or Parkinson's disease), lung disease (e.g. asthma, COPD or pulmonary idiopathic fibrosis), liver disease (e.g. NASH syndrome, viral hepatitis or cirrhosis), pancreatic disease (e.g. acute pancreatitis or chronic pancreatitis), kidney disease (e.g. acute kidney injury or chronic kidney injury), intestinal disease (e.g. Crohn's disease or Ulcerative Colitis), skin disease (e.g. psoriasis), musculoskeletal disease (e.g. scleroderma), a vessel disorder (e.g. giant cell arteritis), a disorder of the bones (e.g. osteoarthritis, osteoporosis or osteopetrosis disorders), eye disease (e.g. glaucoma or macular degeneration), a disease caused by viral infection (e.g. HIV or AIDS), an autoimmune disease (e.g. Rheumatoid Arthritis, Systemic Lupus Erythematosus or Autoimmune Thyroiditis), cancer or aging.

Anti-cancer compositions and methods

Anti-cancer compositions and methods are described including one or more compounds having the structural formula I: where R is phenyl, where R1 is (CH2)n—Se—C(═NH)—NH2, where R2 is (CH2)n—Se—C(═NH)—NH

Diphenylmethyl compounds useful as muscarinic receptor antagonists

This invention provides compounds of formula I: wherein a, b, c, e, m, n, Ar1, R1, R2, R3, R4a, R4b, R5 and R6 are as defined in the specification. The compounds of fo